Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
UNCY

UNCY - Unicycive Therapeutics, Inc. Stock Price, Fair Value and News

$7.01-0.19 (-2.64%)
Market Closed

Price Targets

UNCY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

UNCY Price Action

Last 7 days

6.2%

Last 30 days

18.2%

Last 90 days

45.7%

Trailing 12 Months

30.1%

UNCY RSI Chart

UNCY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

UNCY Valuation

Market Cap

150.7M

Price/Earnings (Trailing)

-4.51

Price/Sales (Trailing)

163.97

Price/Free Cashflow

-5.04

UNCY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

UNCY Fundamentals

UNCY Revenue

Revenue (TTM)

675.0K

UNCY Earnings

Earnings (TTM)

-33.4M

Earnings Growth (Yr)

-46.75%

Earnings Growth (Qtr)

6.76%

UNCY Profitability

Return on Equity

-89.15%

Return on Assets

-66.02%

Free Cashflow Yield

-19.83%

UNCY Investor Care

Shares Dilution (1Y)

107.05%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023882.0K813.0K744.0K675.0K
2022000951.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Unicycive Therapeutics, Inc.

UNCY
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
 CEO
 WEBSITEhttps://unicycive.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Unicycive Therapeutics, Inc. Frequently Asked Questions

UNCY is the stock ticker symbol of Unicycive Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Unicycive Therapeutics, Inc. is 150.65 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check UNCY's fair value in chart for subscribers.

The fair value guage provides a quick view whether UNCY is over valued or under valued. Whether Unicycive Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Unicycive Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UNCY.

As of Wed Jan 28 2026, UNCY's PE ratio (Price to Earnings) is -4.51 and Price to Sales (PS) ratio is 163.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UNCY PE ratio will change depending on the future growth rate expectations of investors.